ID

45171

Beschreibung

Principal Investigator: Zemin Zhang, PhD, Genentech Inc., South San Francisco, CA, USA MeSH: Lung Neoplasms,Carcinoma, Non-Small-Cell Lung https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000299 Version 1 Whole genome sequencing was applied to tumor and adjacent normal lung tissue in an individual non-small-cell lung cancer patient. We present an analysis of somatic changes identified throughout the tumor genome, including single-nucleotide variants, copy number variants, and large-scale chromosomal rearrangements. Over 50,000 high-confidence single-nucleotide variants were identified, revealing evidence of substantial smoking-related DNA damage as well as distinct mutational pressures within the tumor resulting in uneven distribution of somatic mutations across the genome. Version 2 Lung cancer is a highly heterogeneous disease in terms of both underlying genetic lesions and response to therapeutic treatments. We performed deep whole genome sequencing and transcriptome sequencing on 19 lung cancer cell lines and 3 lung tumor/normal pairs. Overall, our data show that cell line models exhibit similar mutation spectra to human tumor samples. Smoker and never-smoker cancer samples exhibit distinguishable patterns of mutations. A number of epigenetic regulators are frequently altered by mutations or copy number changes. A systematic survey of splice-site mutations identified over 100 splice site mutations associated with cancer specific aberrant splicing, including mutations in several known cancer-related genes. Differential usages of splice isoforms were also studied. Taken together, these data present a comprehensive genomic landscape of a large number of lung cancer samples and further demonstrate that cancer specific alternative splicing is a widespread phenomenon that has potential utility as therapeutic biomarkers.

Link

dbGaP study = phs000299

Stichworte

  1. 22.08.22 22.08.22 - Simon Heim
  2. 12.10.22 12.10.22 - Adrian Schulz
Rechteinhaber

Zemin Zhang, PhD, Genentech Inc., South San Francisco, CA, USA

Hochgeladen am

12. Oktober 2022

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0

Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Itemgroup Kommentare für :

Item Kommentare für :


Keine Kommentare

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

dbGaP phs000299 Genentech Lung Cancer Sequencing

Eligibility Criteria

Inclusion and exclusion criteria
Beschreibung

Inclusion and exclusion criteria

Version 1
Beschreibung

Version 1

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0333052
A single patient sample was selected based primarily on tumor content (95%) and available tissue. Pathology examination determined a diagnosis of stage T2N1M0 disease with positive TTF1 and negative CK5 by immunohistochemistry to confirm a diagnosis of poorly differentiated adenocarcinoma. A portion of lung tissue with no apparent tumor infiltration was used as the matched normal control.
Beschreibung

A single patient sample was selected based primarily on tumor content (95%) and available tissue. Pathology examination determined a diagnosis of stage T2N1M0 disease with positive TTF1 and negative CK5 by immunohistochemistry to confirm a diagnosis of poorly differentiated adenocarcinoma. A portion of lung tissue with no apparent tumor infiltration was used as the matched normal control.

Datentyp

boolean

Alias
UMLS CUI [1,1]
C1706256
UMLS CUI [1,2]
C1512693
UMLS CUI [1,3]
C4288090
UMLS CUI [1,4]
C0178759
UMLS CUI [1,5]
C0021044
UMLS CUI [2,1]
C0009932
UMLS CUI [2,2]
C1512693
UMLS CUI [2,3]
C1302449
UMLS CUI [2,4]
C4745116
Version 2
Beschreibung

Version 2

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0333052
Patients that were diagnosed with lung cancer were included in the study. Also included in the study are lung cancer cell lines obtained from ATCC.
Beschreibung

Patients that were diagnosed with lung cancer were included in the study. Also included in the study are lung cancer cell lines obtained from ATCC.

Datentyp

boolean

Alias
UMLS CUI [1,1]
C1512693
UMLS CUI [1,2]
C0242379
UMLS CUI [2,1]
C1512693
UMLS CUI [2,2]
C0242379
UMLS CUI [2,3]
C0334227

Ähnliche Modelle

Eligibility Criteria

Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
Inclusion and exclusion criteria
Version 1
Item
Version 1
boolean
C0333052 (UMLS CUI [1,1])
A single patient sample was selected based primarily on tumor content (95%) and available tissue. Pathology examination determined a diagnosis of stage T2N1M0 disease with positive TTF1 and negative CK5 by immunohistochemistry to confirm a diagnosis of poorly differentiated adenocarcinoma. A portion of lung tissue with no apparent tumor infiltration was used as the matched normal control.
Item
A single patient sample was selected based primarily on tumor content (95%) and available tissue. Pathology examination determined a diagnosis of stage T2N1M0 disease with positive TTF1 and negative CK5 by immunohistochemistry to confirm a diagnosis of poorly differentiated adenocarcinoma. A portion of lung tissue with no apparent tumor infiltration was used as the matched normal control.
boolean
C1706256 (UMLS CUI [1,1])
C1512693 (UMLS CUI [1,2])
C4288090 (UMLS CUI [1,3])
C0178759 (UMLS CUI [1,4])
C0021044 (UMLS CUI [1,5])
C0009932 (UMLS CUI [2,1])
C1512693 (UMLS CUI [2,2])
C1302449 (UMLS CUI [2,3])
C4745116 (UMLS CUI [2,4])
Version 2
Item
Version 2
boolean
C0333052 (UMLS CUI [1,1])
Patients that were diagnosed with lung cancer were included in the study. Also included in the study are lung cancer cell lines obtained from ATCC.
Item
Patients that were diagnosed with lung cancer were included in the study. Also included in the study are lung cancer cell lines obtained from ATCC.
boolean
C1512693 (UMLS CUI [1,1])
C0242379 (UMLS CUI [1,2])
C1512693 (UMLS CUI [2,1])
C0242379 (UMLS CUI [2,2])
C0334227 (UMLS CUI [2,3])

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video